Hernandez-Padilla Laura, Duran-Maldonado Mayra X, Martinez-Alcantar Lorena, Rodriguez-Zavala Jose S, Campos-Garcia Jesus
Laboratorio de Biotecnología Microbiana, Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mich, México.
Departamento de Bioquímica, Instituto Nacional de Cardiología, México City, México.
Curr Cancer Drug Targets. 2025;25(3):230-243. doi: 10.2174/0115680096285034240323035013.
Human cervix adenocarcinoma (CC) caused by papillomavirus is the third most common cancer among female malignant tumors. Bioactive compounds such as cyclodipeptides (CDPs) possess cytotoxic effects in human cervical cancer HeLa cells mainly by blocking the PI3K/Akt/mTOR pathway and subsequently inducing gene expression by countless transcription regulators. However, the upstream elements of signaling pathways have not been well studied.
To elucidate the cytotoxic and antiproliferative responses of the HeLa cell line to CDPs by a transcriptomic analysis previously carried out, we identified by immunochemical analyses, differential expression of genes related to the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) receptors. Furthermore, molecular docking was carried out to evaluate the interactions of CDPs with the EGF and MET substrate binding sites.
Immunochemical and molecular docking analyses suggest that the HGF/MET receptor participation in CDPs cytotoxic effect was independent of the protein expression levels. However, protein modulation of downstream Met-targets occurred due to the inhibition of phosphorylation of the HGF/MET receptor. Results suggest that the antiproliferative and cytotoxicity of CDPs in HeLa cells involve the HGF/MET receptor upstream of PI3K/Akt/mTOR pathway; assays with the human breast cancer MCF-7 and MDA-MB-231cell lines supported the finding.
Data provide new insights into the molecular mechanisms involved in CDPs cytotoxicity and antiproliferative effects, suggesting that the signal transduction mechanism may be related to the inhibition of the phosphorylation of the EGF/MET receptor at the level of substrate binding site by an inhibition mechanism similar to that of Gefitinib and Foretinib anti-neoplastic drugs.
由乳头瘤病毒引起的人类宫颈腺癌(CC)是女性恶性肿瘤中第三常见的癌症。环二肽(CDPs)等生物活性化合物主要通过阻断PI3K/Akt/mTOR途径并随后由无数转录调节因子诱导基因表达,从而对人宫颈癌HeLa细胞产生细胞毒性作用。然而,信号通路的上游元件尚未得到充分研究。
为了通过先前进行的转录组分析阐明HeLa细胞系对CDPs的细胞毒性和抗增殖反应,我们通过免疫化学分析确定了与肝细胞生长因子/间充质上皮转化因子(HGF/MET)受体相关的基因的差异表达。此外,进行分子对接以评估CDPs与表皮生长因子(EGF)和MET底物结合位点的相互作用。
免疫化学和分子对接分析表明,HGF/MET受体参与CDPs的细胞毒性作用与蛋白质表达水平无关。然而,由于HGF/MET受体磷酸化的抑制,下游Met靶点发生了蛋白质调节。结果表明,CDPs在HeLa细胞中的抗增殖和细胞毒性作用涉及PI3K/Akt/mTOR途径上游的HGF/MET受体;用人乳腺癌MCF-7和MDA-MB-231细胞系进行的试验支持了这一发现。
数据为CDPs细胞毒性和抗增殖作用所涉及的分子机制提供了新的见解,表明信号转导机制可能与吉非替尼和福瑞替尼等抗肿瘤药物类似的抑制机制在底物结合位点水平抑制EGF/MET受体磷酸化有关。